TScan Therapeutics (TCRX)
(Real Time Quote from BATS)
$8.60 USD
+0.59 (7.37%)
Updated May 14, 2024 12:24 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TCRX 8.60 +0.59(7.37%)
Will TCRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TCRX
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
TCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
Other News for TCRX
Buy Rating Affirmed: TScan Therapeutics’ Innovative TCR-T Therapy and Strategic Milestones Promising for 2024
TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024
Promising Clinical Results and Robust Financial Position Warrant a Buy Rating for TScan Therapeutics
TScan Therapeutics GAAP EPS of -$0.32, revenue of $0.56M
Fly Intel: Pre-market Movers